

SUPPLEMENTARY TABLE S2. STRATIFIED ANALYSES OF THE VITAMIN D RECEPTOR *BsmI* POLYMORPHISM ON OSTEOPOROSIS RISK

	n	Cases/controls	Bb vs. BB		bb vs. BB		bb vs. BB/Bb		Bb/bb vs. BB	
			OR (95% CI) <sup>a</sup>	P <sup>heterogeneity</sup>	OR (95% CI) <sup>a</sup>	P <sup>heterogeneity</sup>	OR (95% CI) <sup>a</sup>	P <sup>heterogeneity</sup>	OR (95% CI) <sup>a</sup>	P <sup>heterogeneity</sup>
Total	26	2274/3150	0.87 (0.69–1.10) <sup>a</sup>	0.007	0.61 (0.40–0.92) <sup>a</sup>	<0.001	0.70 (0.52–0.95) <sup>a</sup>	<0.001	0.75 (0.56–1.00) <sup>a</sup>	<0.001
Ethnicities										
African	2	150/120	0.64 (0.29–1.43)	0.49	0.06 (0.03–1.13)	0.20	0.08 (0.04–1.15)	0.18	0.18 (0.09–0.37)	0.11
Asian	5	477/405	0.64 (0.27–1.53) <sup>a</sup>	0.03	0.42 (0.10–1.84) <sup>a</sup>	<0.001	0.64 (0.26–1.59) <sup>a</sup>	<0.001	0.48 (0.15–1.62) <sup>a</sup>	<0.001
Caucasian	13	1211/2003	0.86 (0.62–1.19) <sup>a</sup>	0.02	0.66 (0.40–1.06) <sup>a</sup>	<0.001	0.76 (0.57–1.01) <sup>a</sup>	0.005	0.78 (0.54–1.13) <sup>a</sup>	0.001
Turkish	5	395/422	1.23 (0.85–1.78)	0.31	0.86 (0.56–1.31)	0.85	0.80 (0.58–1.10)	0.32	1.08 (0.76–1.53)	0.92
Post	20	1863/2666	0.90 (0.68–1.18) <sup>a</sup>	0.002	0.62 (0.38–1.03) <sup>a</sup>	<0.001	0.68 (0.46–0.98) <sup>a</sup>	<0.001	0.77 (0.54–1.09) <sup>a</sup>	<0.001
HWE in controls										
HWE	17	1557/2474	0.91 (0.75–1.10)	0.16	0.68 (0.45–1.03) <sup>a</sup>	<0.001	0.78 (0.60–1.01) <sup>a</sup>	<0.001	0.79 (0.58–1.07) <sup>a</sup>	0.001
HWD	9	717/676	0.83 (0.47–1.47) <sup>a</sup>	0.002	0.43 (0.16–1.19) <sup>a</sup>	<0.001	0.51 (0.21–1.20) <sup>a</sup>	<0.001	0.62 (0.32–1.20) <sup>a</sup>	<0.001

<sup>a</sup>Random-effects model was used if  $p_{\text{heterogeneity}} < 0.10$ .

$p_{\text{heterogeneity}}$ ,  $p$  value of Q-test for heterogeneity test.

Post, postmenopausal women; HWE, Hardy–Weinberg equilibrium; HWD, Hardy–Weinberg disequilibrium.